.Attributes Medicine, Posted online: 13 September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized phase 3b/4 DESTINY-Breast12 research, trastuzumab deruxtecan (T-DXd) procedure of individuals along with HER2+ sophisticated bosom cancer and also energetic or even stable mind metastases revealed regular intracranial activity and systemic effectiveness of T-DXd.